Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

  • Berta Laquente1,
  • Jose Lopez-Martin2,
  • Donald Richards3,
  • Gerald Illerhaus4,
  • David Z. Chang5,
  • George Kim6,
  • Philip Stella7,
  • Dirk Richel8,
  • Cezary Szcylik9,
  • Stefano Cascinu10,
  • G. L. Frassineti11,
  • Tudor Ciuleanu12,
  • Karla Hurt13,
  • Scott Hynes13,
  • Ji Lin13,
  • Aimee Bence Lin13,
  • Daniel Von Hoff14 and
  • Emiliano Calvo15Email author
BMC Cancer201717:137

https://doi.org/10.1186/s12885-017-3131-x

Received: 2 August 2016

Accepted: 9 February 2017

Published: 15 February 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
2 Aug 2016 Submitted Original manuscript
3 Oct 2016 Reviewed Reviewer Report - John McAuliffe
19 Oct 2016 Reviewed Reviewer Report - Motoyoshi Tanaka
17 Nov 2016 Author responded Author comments - Berta Laquente
Resubmission - Version 2
17 Nov 2016 Submitted Manuscript version 2
15 Dec 2016 Author responded Author comments - Berta Laquente
Resubmission - Version 3
15 Dec 2016 Submitted Manuscript version 3
20 Jan 2017 Author responded Author comments - Berta Laquente
Resubmission - Version 4
20 Jan 2017 Submitted Manuscript version 4
6 Feb 2017 Author responded Author comments - Berta Laquente
Resubmission - Version 5
6 Feb 2017 Submitted Manuscript version 5
Publishing
9 Feb 2017 Editorially accepted
15 Feb 2017 Article published 10.1186/s12885-017-3131-x

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Institut Català d’Oncologia-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge)
(2)
University Hospital and Research Institute
(3)
US Oncology Research
(4)
Hematology, Onkology, and Palliative Care, Klinikum Stuttgart
(5)
Virginia Oncology Associates, Eastern Virginia Medical School, US Oncology Research
(6)
21st Century Oncology, University of Florida Health Oncology
(7)
St. Joseph Mercy Hospital
(8)
Academic Medical Center
(9)
Department of Oncology, Military Institute of Medicine
(10)
Department of Oncology and Hematology, Universitá di Modena e Reggio Emilia, Policlinico di Modena
(11)
Department of Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
(12)
Institute of Oncology Ion Chiricuta, University of Medicine and Pharmacy Iuliu Hatieganu
(13)
Eli Lilly and Company
(14)
Translational Genomics Research Institute (TGen) and HonorHealth Research Institute
(15)
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro

Advertisement